This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent. Top assignee: Imvision Gmbh. Active years: 2009.
Company Filing History:
Years Active: 2009
Title: Innovations in Immunology: The Contributions of Sabine Fluckiger
Introduction
Sabine Fluckiger, an innovative inventor based in Davos-Platz, Switzerland, has made significant strides in the field of immunology. With a focus on developing solutions for allergies and vaccination, Fluckiger's work exemplifies the transformative potential of modern science and technology. Her notable contribution includes a patent that lays the groundwork for new therapeutic approaches in immune modulation.
Latest Patents
Fluckiger holds a patent for Modular Antigen Transporter Molecules (MAT molecules) designed for modulating immune reactions. These MAT molecules serve as vaccines and can also be employed in the treatment of allergies. The patent describes a system comprising three essential modules: a translocation module that facilitates the transport of the MAT molecule into the cell's interior; a targeting module that directs the MAT molecule to intracellular organelles responsible for antigen processing and loading; and an antigen module which encompasses an allergen.
Career Highlights
Currently, Sabine Fluckiger is associated with Imvision GmbH, where she applies her expertise in biopharmaceutical research. Her singular patent reflects her commitment to advancing the understanding and treatment of allergic reactions and improving immunological responses through innovative technologies.
Collaborations
Fluckiger collaborates with esteemed colleagues such as Norbert Lamping and Reto Crameri, who share a dedication to pushing the boundaries of scientific research and application. Together, they contribute to a dynamic work environment that fosters innovation and encourages the development of groundbreaking therapies.
Conclusion
As a pioneering inventor, Sabine Fluckiger's contributions to the field of immunology are noteworthy. Her patent for Modular Antigen Transporter Molecules showcases the potential to revolutionize how we approach vaccination and allergy treatment. With continued support from her colleagues at Imvision GmbH, Fluckiger is poised to influence the future of medical science positively.